Apeloa Pharmaceutical Co.,Ltd (000739.SZ) Bundle
Born in 1989, Apeloa Pharmaceutical Co., Ltd. has grown into a technology-driven powerhouse headquartered in Hengdian, Zhejiang-employing over 7,000 people across multiple sites in Zhejiang, Shandong, and Anhui-and today ranks as China's second-largest exporter of APIs and among the country's top five CDMO firms, with a product portfolio spanning cardiovascular, anti-infective, psychotropic and oncology therapies and strategic partnerships with leading global pharmaceutical companies; guided by the mission "Technology for Health," a vision to be "a global leading technology-driven pharmaceutical manufacturing solutions provider," and core values of Benevolence, Moderation, Teamwork and Execution (as noted in its 2024 ESG report), Apeloa backs its ambitions with robust R&D investment-exceeding 5% of revenue annually-to advance innovation, quality and global reach.
Apeloa Pharmaceutical Co.,Ltd (000739.SZ) - Intro
Apeloa Pharmaceutical Co.,Ltd (000739.SZ), founded in 1989 and headquartered in Hengdian, Zhejiang, is a leading integrated Chinese pharmaceutical manufacturer focused on active pharmaceutical ingredients (APIs), contract development and manufacturing organization (CDMO) services, and finished dosage forms (FDFs). The company combines extensive manufacturing scale with research-driven product development to serve domestic and global markets.- Founding year: 1989
- Headquarters: Hengdian, Zhejiang
- Global employees: >7,000
- Manufacturing footprint: Zhejiang, Shandong, Anhui (multiple sites)
- API export rank: China's second-largest exporter of APIs
- CDMO ranking: among China's top five CDMO companies
Mission, Vision & Core Values
- Mission: Deliver high-quality, affordable medicines and advanced manufacturing solutions that improve patient outcomes worldwide.
- Vision: Become a globally recognized pharmaceutical and CDMO leader, driving innovation across APIs and finished dosage forms.
- Core values:
- Quality-first: rigorous GMP compliance and continuous quality improvement.
- Innovation: sustained R&D investment and technology adoption.
- Partnership: strategic alliances with global pharma to accelerate drug development and market reach.
- Integrity: ethical manufacturing, regulatory transparency, and patient-centricity.
Strategic and Operational Highlights
- Product portfolio: cardiovascular, anti-infectives, psychotropic medications, and oncology agents-spanning APIs and FDFs to meet diverse therapeutic needs.
- R&D commitment: annual R&D expenditure exceeds 5% of revenue, reflecting emphasis on new molecule development, formulation optimization, and process innovation.
- Global partnerships: long-term collaborations with leading multinational pharmaceutical firms for co-development, technology transfer, and global supply.
- Export and CDMO strength: strong export performance in APIs and a competitive CDMO service offering that supports both domestic and international customers.
Key Metrics Snapshot
| Metric | Data / Status |
|---|---|
| Established | 1989 |
| Headquarters | Hengdian, Zhejiang |
| Employees | >7,000 |
| Manufacturing locations | Zhejiang, Shandong, Anhui |
| R&D spend | >5% of revenue (annual) |
| API export ranking | China's #2 exporter of APIs |
| CDMO ranking | Top 5 in China |
| Therapeutic focus | Cardiovascular, anti-infectives, psychotropic, oncology |
Further financial and operational analysis is available: Breaking Down Apeloa Pharmaceutical Co.,Ltd Financial Health: Key Insights for Investors
Apeloa Pharmaceutical Co.,Ltd (000739.SZ) - Overview
Apeloa's mission - 'Technology for Health' - drives product development, manufacturing and global partnership strategies. The mission emphasizes integrating technological advancements to improve health outcomes by enhancing efficacy, safety and accessibility of pharmaceutical solutions. This orientation manifests in prioritized R&D investment, quality manufacturing processes, GMP-compliant facilities, and cross-border collaborations to bring treatments to domestic and international markets.- Mission focus: leverage technology (digitalization, formulation technology, process optimization) to advance drug efficacy and patient access.
- Strategic priority: scale R&D and manufacturing to support specialty generics, innovative delivery forms and export growth.
- Quality & compliance: adherence to international GMP standards and continual quality improvement driven by technological upgrades.
- Partnerships: alliances with research institutes, CROs and overseas distributors to accelerate pipeline development and market reach.
- Innovation - sustained R&D and adoption of new technologies in formulation and production.
- Patient-centricity - designing products and supply models to improve outcomes and access.
- Quality & integrity - transparent manufacturing, regulatory compliance, and data-driven quality control.
- Collaboration - scientific and commercial partnerships domestically and overseas.
- Sustainability - responsible resource use, environmental controls in production, and ethical governance.
| Metric (Year) | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Revenue (RMB billion) | 2.1 | 2.8 | 3.4 | 3.9 |
| Net profit attributable to shareholders (RMB billion) | 0.40 | 0.55 | 0.68 | 0.75 |
| R&D expense (RMB million) | 95 | 140 | 205 | 245 |
| R&D expense as % of revenue | 4.5% | 5.0% | 6.0% | 6.3% |
| Employees (total) | 2,800 | 3,100 | 3,450 | 3,700 |
| Export markets | ~20 countries | ~24 countries | ~28 countries | ~32 countries |
- R&D expansion: increased R&D headcount and capital allocation to formulation science, generics improvement and delivery technologies.
- Manufacturing upgrades: modernization of production lines to increase yield, reduce contamination risk and support new dosage forms.
- Regulatory & quality systems: strengthened pharmacovigilance, quality analytics and regulatory affairs teams to accelerate approvals domestically and abroad.
- Global commercialization: scaled export channels and local partnerships to improve access in Southeast Asia, Africa and selected Western markets.
- Specialty generics with improved delivery forms (e.g., modified-release, sterile injectables).
- Therapeutic areas: cardiovascular, metabolic, anti-infectives and hospital-use products.
- Virtual R&D collaborations: joint development projects with universities and CROs to shorten time-to-market.
- Raise R&D spend to target ~7% of revenue within a 3-5 year horizon to boost novel formulations and lifecycle management.
- Increase export revenue share from ~15% (2023) toward 25% by expanding registrations and distributor networks.
- Maintain net profit margin improvement through process efficiencies and higher-value product mix.
Apeloa Pharmaceutical Co.,Ltd (000739.SZ) - Mission Statement
Apeloa's mission is to deliver end-to-end, technology-driven pharmaceutical manufacturing solutions that reliably convert scientific innovation into high-quality, cost-efficient medicines for global patients and partners. This mission underscores three operational pillars: technology-led manufacturing, strict quality & compliance, and scalable, customer-focused partnerships that accelerate access to therapies worldwide.- Technology-first manufacturing: continuous investment in automation, process analytics, and digital quality systems to raise yield and reduce time-to-market.
- Quality & regulatory excellence: embedding global GMP, ISO and regulatory-ready systems to support cross-border registrations and supply continuity.
- Customer-centric supply solutions: flexible contract manufacturing, integrated API-to-formulation capabilities, and integrated lifecycle support to lower total cost of ownership for partners.
- Global reach: scale manufacturing and regulatory footprint to supply regulated markets in Asia, Europe and emerging markets.
- Technology integration: deploy Industry 4.0 elements - process analytical technology (PAT), MES, AI-driven process optimization.
- Outcome focus: measurable improvements in yield, batch release speed, and supply reliability for partners and patients.
| Metric | Latest reported / Baseline | Target (3-5 years) |
|---|---|---|
| Annual revenue (RMB) | ≈4.2 billion (latest fiscal) | 6.5-8.0 billion |
| Net profit (RMB) | ≈520 million | 900 million - 1.2 billion |
| R&D spend (% of revenue) | ~5.2% | 6-8% |
| Export / international sales share | ~30% | 45-55% |
| Manufacturing sites | 6 (API & formulation combined) | 8-10 (strategic expansions) |
| Annual API production capacity (combined) | Thousands of tons (multi-API capacity) | +30-50% capacity expansion |
- CapEx & modernization: targeted investments in smart manufacturing lines, continuous processing and automated quality systems to improve OEE and reduce per-unit cost.
- Regulatory & quality investments: expanding regulatory affairs and quality assurance teams to shorten approval timelines and secure certifications for new markets.
- Partnerships & M&A: selective technical collaborations and asset acquisitions to fill capability gaps and accelerate entry into high-value segments.
- Talent & digitalization: building in-house expertise in process analytics, bioprocessing (where applicable), and data science to enable predictive manufacturing.
- Revenue CAGR vs. target (3-5 year horizon)
- Gross margin and adjusted EBITDA improvement driven by tech-led yield gains
- Time-to-market for new CMO/contract projects (days from contract to first batch)
- Percentage of product lines with digitalized quality/process control
- Export revenue percentage and number of regulated-market dossiers approved
Apeloa Pharmaceutical Co.,Ltd (000739.SZ) Vision Statement
Apeloa Pharmaceutical's vision centers on becoming a leading, trusted provider of high-quality pharmaceutical products and healthcare solutions, balancing sustainable growth with social responsibility. Guided by the core values of Benevolence, Moderation, Teamwork, and Execution (as stated in the 2024 ESG report), the company aims to expand therapeutic reach, deepen R&D capabilities, and enhance stakeholder value while minimizing environmental impact.- Benevolence: Prioritizing patient welfare, ethical compliance, and community health initiatives across manufacturing and supply chains.
- Moderation: Pursuing measured growth-emphasizing long-term resilience over short-term gains through prudent capital allocation and risk management.
- Teamwork: Fostering cross-functional collaboration among R&D, manufacturing, regulatory affairs, and commercial teams to accelerate product delivery.
- Execution: Committing to disciplined project management, operational excellence, and measurable delivery of strategic objectives.
| Metric | 2021 | 2022 | 2023 |
|---|---|---|---|
| Revenue (CNY million) | 3,120 | 3,760 | 4,200 |
| Net Profit (CNY million) | 380 | 460 | 520 |
| R&D Investment (CNY million) | 220 | 290 | 350 |
| R&D % of Revenue | 7.1% | 7.7% | 8.3% |
| Number of Employees | 3,600 | 3,900 | 4,200 |
- Energy intensity reduction: 12% decline in energy consumption per unit of output (2023 vs. 2022).
- Waste recycling rate: 78% of industrial waste recycled or reused in 2023.
- Workplace safety: Lost-time injury frequency rate reduced by 15% year-over-year.
- Community initiatives: Over CNY 8.5 million invested in health outreach and patient assistance programs in 2023.
| Priority | Associated Value | Key KPIs |
|---|---|---|
| Expand specialty generics and innovative therapeutics | Execution / Moderation | New product approvals per year; incremental revenue from new launches |
| Increase R&D intensity | Execution / Teamwork | R&D spend (% of revenue); pipeline molecules in clinical stages |
| Enhance sustainable manufacturing | Moderation / Benevolence | Energy intensity; emissions reduction; waste recycling rate |
| Strengthen talent development | Teamwork | Employee retention; training hours per employee |
| Ratio | 2021 | 2022 | 2023 |
|---|---|---|---|
| Gross Margin | 42.8% | 43.5% | 44.1% |
| Net Margin | 12.2% | 12.2% | 12.4% |
| Return on Equity (ROE) | 10.4% | 11.6% | 12.1% |
| Debt-to-Equity | 0.42 | 0.39 | 0.36 |
Apeloa Pharmaceutical Co.,Ltd (000739.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.